Natixis Advisors L.P. Has $140.17 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Natixis Advisors L.P. raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 141.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,129,570 shares of the medical device company's stock after purchasing an additional 661,584 shares during the period. Natixis Advisors L.P. owned 0.29% of DexCom worth $140,168,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in DXCM. Valley National Advisers Inc. lifted its position in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock valued at $30,000 after purchasing an additional 103 shares during the period. MV Capital Management Inc. raised its position in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock valued at $34,000 after acquiring an additional 138 shares during the period. Washington Trust Advisors Inc. raised its position in shares of DexCom by 120.6% in the 4th quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company's stock valued at $44,000 after acquiring an additional 193 shares during the period. NBC Securities Inc. acquired a new stake in shares of DexCom in the 3rd quarter valued at approximately $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new stake in shares of DexCom in the 3rd quarter valued at approximately $48,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 2,624 shares of the firm's stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the transaction, the executive vice president now directly owns 68,682 shares of the company's stock, valued at $9,618,227.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the firm's stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares of the company's stock, valued at approximately $5,839,974.37. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Jon Brown sold 2,624 shares of the firm's stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the sale, the executive vice president now directly owns 68,682 shares of the company's stock, valued at approximately $9,618,227.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 190,004 shares of company stock valued at $25,610,270. 0.41% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. StockNews.com upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research report on Wednesday. Canaccord Genuity Group increased their price target on shares of DexCom from $144.00 to $145.00 and gave the company a "buy" rating in a research report on Friday, April 26th. Raymond James increased their price target on shares of DexCom from $151.00 to $160.00 and gave the company a "strong-buy" rating in a research report on Friday, April 26th. Citigroup increased their target price on DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada started coverage on DexCom in a research note on Tuesday, March 12th. They set an "outperform" rating and a $165.00 target price for the company. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $141.67.

DexCom Stock Up 0.6 %

Shares of DXCM traded up $0.77 during mid-day trading on Thursday, hitting $126.65. 2,311,384 shares of the company's stock were exchanged, compared to its average volume of 3,046,284. The company has a market cap of $50.37 billion, a PE ratio of 81.71, a P/E/G ratio of 2.18 and a beta of 1.23. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The company has a 50-day simple moving average of $131.87 and a 200 day simple moving average of $119.62. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The company had revenue of $921.00 million during the quarter, compared to analysts' expectations of $911.20 million. On average, research analysts forecast that DexCom, Inc. will post 1.77 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.